Cancer research through clinical trials has paved the way to make great strides in the treatment of cancer. Willamette Valley Cancer Institute and Research Center (WVCI) participates in clinical trials through Sarah Cannon Research Institute (SCRI), a joint venture with US Oncology Research and one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 600 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. Through our partnership, we can provide patients with access to the latest in cancer treatment options through clinical trials.
Several of our physicians here at Willamette Valley serve on research committees to develop new protocols and to determine future studies.
Clinical trials are research studies designed to develop new and better treatment therapies for all types of cancer. They are the centerpiece of the drug-testing system in the United States. A clinical trial is often used to learn if a new cancer treatment is more effective and/or has fewer harmful side effects than the current, standard treatment. Because all new cancer treatment therapies must be evaluated through clinical trials, the more people who participate in cancer research trials, the sooner other cancer patients can benefit from life-saving treatment options.
Physicians and cancer researchers design clinical trials, and these trials are conducted according to strict scientific and ethical principles. Before each study begins, a protocol is developed describing both the process and the necessity of each part of the study. To ensure the study is conducted fairly, and patients are well-informed of their rights, third-party experts will review the protocol. Each study has eligibility criteria for who can or cannot participate in the study, which may include the type of cancer, past cancer treatment regimens, age, gender, medical history, and current health status.
A concern among patients is whether they may be given an inactive treatment, called a placebo. The use of placebos in cancer clinical trials is rare, but it does happen. In most trials, cancer research participants are either given the new treatment or they are given an existing treatment already approved to treat their cancer.
Clinical trial randomization is the process of assigning patients by chance to groups that receive different treatments. A select number of people will receive the new treatment being tested (the investigational group), while others will receive the standard treatment (the control group) that is already available. Oftentimes, neither the doctor nor the patient knows which cancer treatment they are receiving. This is so the results cannot be influenced by conscious or unconscious bias. At several points during and at the end of the clinical trial, researchers compare the groups to see which treatment is more effective or has fewer side effects.
Randomization happens in all Phase III trials and some Phase II trials.
Clinical trials are conducted in a series of steps, called phases, and each phase is designed to answer a separate research question. Most new cancer treatments only go through Phases I, II, and III, as Phase IV is not always necessary for proving a new cancer treatment safe and effective.
Phase II trials usually involve more people than the Phase I trials, but less than 100 people all meet specific requirements set by the investigators.
Our patients come first. If you qualify for a clinical trial, our research specialists will reach out to talk to you. You will be given all of the information about potential benefits and risks, and provided a detailed explanation of the treatment being tested. Those who take part in clinical trials receive close, personal attention and careful monitoring. Participation is voluntary, and patients can withdraw from a clinical trial at any time. If your oncologist feels that it’s not effective for you, s/he may also elect to stop your participation.
If you’re interested in participating in a trial, your WVCI oncologist can help determine if you’re a candidate. Any cancer patients considering a clinical trial should know as much about it as possible, including what is being studied and what they can expect during the trial.
Visit US Oncology's website for additional information and resources to help you learn more about clinical trials and understand your rights as a research participant.
For more information about cancer research or clinical trials at WVCI, call and speak to someone in our WVCI Clinical Research Team at 541-683-5001.